WSAAI 2025 62nd Annual Scientific Session

Waimea, HI US
February 9, 2025 to February 13, 2025

 The Western Society of Allergy, Asthma & Immunology consistently delivers high-quality, scientific lectures in the field of Allergy & Clinical Immunology in a unique format promoting attendee interaction with some of the foremost researchers and clinicians in our specialty.  Such conferences have been our notable achievement for over five decades. Among the subjects covered in the upcoming program address various topics around Food Allergy & Immunotherapy,  AERD, Asthma, Itch, EoE, HAE and MCAS.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Western Society of Allergy Asthma & Immunology (WSAAI).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 19 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 19 contact hours.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…

1. Recognize the clinical presentations of AERD, MCAS, tryptasemia, and EoE, and distinguish them from similar conditions.

2. Identify the differential diagnoses and appropriate diagnostic approaches for mast cell disorders and hereditary angioedema (HAE).

3. Evaluate the advantages, limitations, and efficacy of current and emerging treatments for food allergies, asthma, chronic urticaria, HAE, and atopic dermatitis.

4. Discuss novel therapeutic options for eosinophil-associated gastrointestinal disorders and their clinical applications.

5. Apply clinical practice guidelines to develop personalized, comprehensive management plans for conditions such as chronic urticaria, HAE, and food allergies.

6. Examine the biological basis, inflammatory pathways, and long-term consequences of conditions like asthma and atopic dermatitis.

7. Address unique diagnostic and therapeutic challenges, such as patch testing in atopic dermatitis or managing multisegment EGID.

8. Employ innovative strategies for conditions like erythrodermic atopic dermatitis using tailored approaches.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

No commerical support was received for this activity.

Course summary
Available credit: 
  • 19.00 AMA PRA Category 1 Credit™
  • 19.00 Attendance
  • 19.00 CBRN
Course opens: 
02/09/2025
Course expires: 
12/31/2026
Event starts: 
02/09/2025 - 3:00pm CST
Event ends: 
02/13/2025 - 5:45pm CST
Rating: 
0

62nd Annual Scientific Session
February 9-13, 2025

SUNDAY, FEBRUARY 9, 2025

3:00-5:00 PM         REGISTRATION, POSTER SESSION, EXHIBITS 
6:00-8:00 PM         WELCOME RECEPTION

MONDAY, FEBRUARY 10, 2025

6:45-7:00 AM         WELCOME AND INTRODUCTION 
            Andrew White, MD, Program Director/President Elect 
            SESSION MODERATOR: David Elkayam, MD, President

7:00-7:45 AM        The Donald Stevenson, MD Lecture: AERD: Bridging History, Science, and Patient Care
7:45-8:00 AM        Q&A
            Tanya Laidlaw, MD

8:00-8:45 AM        Alphabet Soup: Genetics for the Practicing Allergist 
8:45-9:00 AM        Q&A
            Lori Broderick, MD, PhD

9:00-9:45 AM        Remission in Asthma
9:45-10:00 AM        Q&A
            Rohit Katial, MD

10:00-10:30 AM     BREAK/EXHIBITS/POSTERS

10:30-11:15 AM        Practical Approach to Food Immunotherapy in Childhood
11:15-11:30 AM        Q&A
            Edwin Kim, MD, MS

11:30 AM-12:15 PM    Interpreting an Elevated Tryptase 
12:15-12:30 PM        Q&A
            Jonathan Lyons, MD

TUESDAY, FEBRUARY 11, 2025

11:50 AM-12:20 PM         EXHIBITS/POSTERS

12:20-12:35 PM        Scholarship Recipients: Abstract Introductions

12:35-12:40 PM        SESSION MODERATOR: Amy Wagelie-Steffen, MD, Secretary/Treasurer

12:40-1:25 PM        The Harold S. Nelson, MD Lecture: Biomarkers in Asthma
1:25-1:40 PM        Q&A
            Rohit Katial, MD

1:40-2:25 PM         Itch: The Neuroimmune Perspective 
2:25-2:40 PM         Q&A
            Aaron ver Heul, MD, PhD

2:40-3:25 PM        Eosinophils in the GI Tract: From EoE to EGID 
3:25-3:40 PM         Q&A
            Fei Li Kuang, MD, PhD (virtual presentation)

3:40-4:10 PM         BREAK/EXHIBITS/POSTERS

4:10-4:55 PM        Lessons learned from Primary Atopic Disorders
4:55-5:10 PM         Q&A
            Jonathan Lyons, MD

5:10-5:55 PM        HAE: Diagnosing, Treating, and Managing the Patient with Hereditary Angioedema
5:55-6:10 PM        Q&A
            Timothy Craig, DO

WEDNESDAY, FEBRUARY 12, 2025

7:00-8:00 AM         WSAAI MEMBER BREAKFAST/BUSINESS MEETING 
7:00-8:00 AM         EXHIBITS/BREAK/POSTERS

8:15-8:30 AM        SESSION MODERATOR: René Anderson-Cowell, MD, Immediate Past President

8:30-9:15 AM        Severe Cutaneous Adverse Drug Reactions: Current Concepts
9:15-9:30 AM        Q&A    
            Neill Peters, MD

9:30-10:15 AM        Practical Approaches to NSAID Hypersensitivity
10:15-10:30 AM      Q&A
            Tanya Laidlaw, MD

10:30-11:15 AM        Compassion and Caring Beyond MCAS: Getting Comfortable with Dysautonomia  
11:15-11:30 AM        Q&A
            Marcus S. Shaker, MD, MSc

11:30 AM-12:00 PM    BREAK/EXHIBITS/POSTERS

12:00-12:45 PM        The Expanding Universe of Autoinflammatory Diseases
12:45-1:00 PM         Q&A
            Lori Broderick, MD, PhD

1:00-1:45 PM        Update in Food Allergy Diagnostics
1:45-2:00 PM        Q&A
          Edwin Kim, MD, MS

THURSDAY, FEBRUARY 13, 2025

12:30 PM-1:00 PM    EXHIBITS/POSTERS

1:00-1:15 PM        SESSION MODERATOR
            Andrew White, MD, Program Director/President Elect

1:15-2:00 PM        Alpha 1- Antitrypsin Deficiency   
2:00-2:15 PM        Q&A
            Timothy Craig, DO

2:15-3:00 PM        Pharmacoequity & Cost-Effective Care in the Allergy Immunology Clinic  
3:00-3:15 PM        Q&A
            Marcus S. Shaker, MD, MSc

3:15-3:45 PM         BREAK/EXHIBITS/POSTERS

3:45-4:30 PM        Contact Dermatitis: Pearls and Pitfalls
4:30-4:45 PM        Q&A
            Neill Peters, MD

4:45-5:30 PM        Chronic Spontaneous Urticaria: The Edge of a New Era 
5:30-5:45 PM        Q&A
            Aaron ver Heul, MD, PhD

5:45 PM            Adjourn

Fairmont Orchid
1 North Kaniku Drive
Kohala Coast
Waimea, HI 96743
United States

All relevant financial relationships with ineligible companies have been mitigated.

Lori Broderick, MD, PhD – Speaker
Independent contractor: Novartis
Speaker: SOBI

Timothy Craig, DO – Speaker
Advisor: Astria, BioCryst, BioMarin, CSL Behring, HAE-A Medical Advisory Board, Ionis, Intellia, KalVista, Pharvaris, Takeda
Consultant: BioCryst; HAE-A Medical Advisory Board
Researcher: BioMarin, Intellia, Pharvaris
Speaker: Astria, CSL Behring, Ionis, KalVista, Takeda

Rohit Katial, MD – Speaker
Advisor: AstraZeneca, Grifols, GSK, Sanofi/Regeneron
Speaker: AstraZeneca, Grifols, Sanofi/Regeneron

Edwin Kim, MD, MS – Speaker
Advisor: ALK, Kenota Health, Ukko Inc.
Consultant: Allakos, Belhaven Biopharma, Cellergy Pharma, DBV Technologies, Genentech, GrowHappy, Hanimune Therapeutics, Novartis, Phylaxis BioScience, Revolo Biotherapeutics, GrowHappy
Stocks/Options: Belhaven Biopharma, Cellergy Pharma, GrowHappy

Tanya Laidlaw, MD – Speaker
Consultant: AstraZeneca, Eli-Lilly, Regeneron, Sanofi/Genzyme

Jonathan Lyons, MD – Speaker
Consultant: Blueprint Medicines, Visterra Inc., Human Biosciences Inc.

Aaron Ver Heul, MD, PhD – Speaker
Advisor: Sanofi-Regeneron
Consultant: Target PharmaSolutions
Researcher: Celldex

David Elkayam, MD - Planner, Moderator
Consultant: Siva
Researcher: Allergy Therapeutics, AstraZeneca, Bellus Health, Genentech, Novartis, Siva, Suzhou

Andrew White, MD - Planner, Moderator
Advisor: Amgen, AstraZeneca, Blueprint, GSK, Optinose, Regeneron/Sanofi
Researcher: AstraZeneca, Regeneron/Sanofi
Speaker: AstraZeneca, Blueprint, Genentech, GSK, Optinose, Regeneron/Sanofi

Amy Wagelie-Steffen, MD - Planner, Moderator
Advisor: BioCryst, Pharming
Consultant: BioCryst, Pharming
Speaker: Amgen, AstraZeneca, Sanofi/Regeneron

Marc Riedl, MD, MS - Planner, Moderator
Consultant: Astria, BioCryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, KalVista, Pfizer, Pharming, Pharvaris, Sanofi/Regeneron, Takeda
Researcher: BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda
Speaker: CSL Behring, Grifols, Pharming, Takeda

The following have no relevant financial relationships with ineligible companies to disclose:

Karol Anderson - Planner
Rene Anderson-Cowell, MD - Planner, Moderator
Jinny Chang, MD - Planner
Kristina James, MD - Planner
Paneez Khoury, MD, MHSc - Speaker
Neill Peters, MD – Speaker
Marcus Shaker, MD – Speaker
Mark Tucker, MD - Planner

Available Credit

  • 19.00 AMA PRA Category 1 Credit™
  • 19.00 Attendance
  • 19.00 CBRN
Please login or create an account to take this course.